Finasteride, c23h36n2o2, is a 4-azasteroid. It is a specific inhibitor of intracellular enzyme type II 5A reductase in the process of metabolism to dihydro. It can effectively reduce dihydroin the blood and prostate, that is, by inhibiting the conversion of to dihydro (DHT), reducing the volume of prostate, improving symptoms, increasing urine flow rate and preventing benign prostatic hyperplasia (BPH)
Finasteride is an antiandrogen which acts by inhibiting type II 5-alpha reductase.It is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses. It is also indicated for use in combination with doxazosin therapy to reduce the risk for symptomatic progression of BPH. Additionally, it is registered in many countries for androgenetic alopecia (male-pattern baldness). Finasteride was approved initially in 1992, a treatment for prostate enlargement, but the sponsor had studied 1 mg of finasterideand demonstrated hair growth in male pattern hair loss
Product Name | Finasteride | |||
CAS | 98319-26-7 | |||
Specification | 99% | |||
Grade | Medicine Grade | |||
Appearance | White or off white crystalline powder | |||
Storage | Keep in cool & dry place, stay away from strong light and heat | |||
Shelf Life | 24 months |
Uses
1. Used for treatment of hair loss;
2. For the treatment of benign prostatic hyperplasia, enlarged prostate shrink, improve urinary flow and improvement of benign prostatic hyperplasia caused symptoms.
Reviews
There are no reviews yet.